Search

Your search keyword '"Khozin, Sean"' showing total 202 results
Start Over Author "Khozin, Sean"
202 results on '"Khozin, Sean"'

1. Towards a Framework for a New Research Ecosystem

Author

Savona, Roberto, Alberini, Cristina Maria, Alessi, Lucia, Baussano, Iacopo, Dellaportas, Petros, Guerra, Ranieri, Khozin, Sean, Modena, Andrea, Pecorelli, Sergio, Rasi, Guido, Siviero, Paolo Daniele, and Stein, Roger M.

Subjects
Economics - General Economics
Abstract

A major gap exists between the conceptual suggestion of how much a nation should invest in science, innovation, and technology, and the practical implementation of what is done. We identify 4 critical challenges that must be address in order to develop an environment conducive to collaboration across organizations and governments, while also preserving commercial rewards for investors and innovators, in order to move towards a new Research Ecosystem., Comment: 20 pages, 1 table, 2 figures

Published
2023

10. Table A1: ICD-9-CM Neoplasm Terms for Lung Cancer from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

Author

Harvey, R. Donald, primary, Bruinooge, Suanna S., primary, Chen, Li, primary, Garrett-Mayer, Elizabeth, primary, Rhodes, Whitney, primary, Stepanski, Edward, primary, Uldrick, Thomas S., primary, Ison, Gwynn, primary, Khozin, Sean, primary, Rubinstein, Wendy S., primary, Schenkel, Caroline, primary, Miller, Robert S., primary, Komatsoulis, George A., primary, Schilsky, Richard L., primary, and Kim, Edward S., primary

Published
2023
Full Text
View/download PDF

17. Unleashing the power of clinical trial data: a proposal for enhancing informed consent and data sharing.

Author

Trippa, Lorenzo and Khozin, Sean

Subjects
DATABASES, MEDICAL information storage & retrieval systems, DATA science, MEDICAL protocols, PATIENTS' rights, PATIENT safety, DIFFUSION of innovations, MEDICAL technology, CLINICAL trials, ARTIFICIAL intelligence, DECISION making in clinical medicine, INFORMED consent (Medical law), COMMUNICATION, ELECTRONIC health records, ACCESS to information, WELL-being, PATIENT participation
Abstract

The article proposes a strategy to enhance informed consent procedures and data sharing to advance the power of clinical trial data. It considers the potential influence of the U.S. Food and Drug Administration (FDA) Informed Consent guidance in the incorporation of amendments to standard consent procedures. It suggests the inclusion of optional provision for patients to request individual data sharing in future informed consent forms, as well as policies for data collection and storage.

Published
2024
Full Text
View/download PDF

18. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

Author

Rajan, Arun, Carter, Corey A, Berman, Arlene, Cao, Liang, Kelly, Ronan J, Thomas, Anish, Khozin, Sean, Chavez, Ariel Lopez, Bergagnini, Isabella, Scepura, Barbara, Szabo, Eva, Lee, Min-Jung, Trepel, Jane B, Browne, Sarah K, Rosen, Lindsey B, Yu, Yunkai, Steinberg, Seth M, Chen, Helen X, Riely, Gregory J, and Giaccone, Giuseppe

Published
2014
Full Text
View/download PDF

22. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data

Author

Reynolds, Kerry L, primary, Arora, Shaily, additional, Elayavilli, Ravikumar Komandur, additional, Louv, William C, additional, Schaller, Teilo H, additional, Khandelwal, Aakanksha, additional, Rothenberg, Mace, additional, Khozin, Sean, additional, Guidon, Amanda C, additional, Dougan, Michael, additional, Zubiri, Leyre, additional, Petrillo, Laura, additional, Sise, Meghan E, additional, Villani, Alexandra-Chloe, additional, Johnson, Douglas B, additional, Rahma, Osama, additional, and Sharon, Elad, additional

Published
2021
Full Text
View/download PDF

23. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

Author

Harvey, R. Donald, primary, Bruinooge, Suanna S., additional, Chen, Li, additional, Garrett-Mayer, Elizabeth, additional, Rhodes, Whitney, additional, Stepanski, Edward, additional, Uldrick, Thomas S., additional, Ison, Gwynn, additional, Khozin, Sean, additional, Rubinstein, Wendy S., additional, Schenkel, Caroline, additional, Miller, Robert S., additional, Komatsoulis, George A., additional, Schilsky, Richard L., additional, and Kim, Edward S., additional

Published
2021
Full Text
View/download PDF

29. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer

Author

Stewart, Mark, primary, Norden, Andrew D., additional, Dreyer, Nancy, additional, Henk, Henry Joe, additional, Abernethy, Amy P., additional, Chrischilles, Elizabeth, additional, Kushi, Lawrence, additional, Mansfield, Aaron S., additional, Khozin, Sean, additional, Sharon, Elad, additional, Arunajadai, Srikesh, additional, Carnahan, Ryan, additional, Christian, Jennifer B., additional, Miksad, Rebecca A., additional, Sakoda, Lori C., additional, Torres, Aracelis Z., additional, Valice, Emily, additional, and Allen, Jeff, additional

Published
2019
Full Text
View/download PDF

30. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

Author

Griffith, Sandra D., primary, Miksad, Rebecca A., additional, Calkins, Geoff, additional, You, Paul, additional, Lipitz, Nicole G., additional, Bourla, Ariel B., additional, Williams, Erin, additional, George, Daniel J., additional, Schrag, Deborah, additional, Khozin, Sean, additional, Capra, William B., additional, Taylor, Michael D., additional, and Abernethy, Amy P., additional

Published
2019
Full Text
View/download PDF

32. Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

Author

Khozin, Sean, primary, Miksad, Rebecca A., additional, Adami, Johan, additional, Boyd, Mariel, additional, Brown, Nicholas R., additional, Gossai, Anala, additional, Kaganman, Irene, additional, Kuk, Deborah, additional, Rockland, Jillian M., additional, Pazdur, Richard, additional, Torres, Aracelis Z., additional, Zhi, Jizu, additional, and Abernethy, Amy P., additional

Published
2019
Full Text
View/download PDF

33. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.

Author

Harvey, R. Donald, primary, Rubinstein, Wendy S., additional, Ison, Gwynn, additional, Khozin, Sean, additional, Chen, Li, additional, Miller, Robert S., additional, Jun, Monika, additional, Stepanski, Edward, additional, Hyde, Brigham, additional, Uldrick, Thomas S., additional, Komatsoulis, George Anthony, additional, Roberts, Jeremy, additional, Garrett-Mayer, Elizabeth, additional, Schilsky, Richard L., additional, Schenkel, Caroline, additional, Kim, Edward S., additional, and Bruinooge, Suanna S., additional

Published
2019
Full Text
View/download PDF

34. Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database.

Author

Chen, Li, primary, Walker, Mark S., additional, Zhi, Jizu, additional, Komatsoulis, George Anthony, additional, Jun, Monika, additional, Stepanski, Edward, additional, Fukushima, Ryan, additional, Lau, Denise, additional, Roberts, Jeremy, additional, Hyde, Brigham, additional, Miller, Robert S., additional, Khozin, Sean, additional, and Rubinstein, Wendy S., additional

Published
2019
Full Text
View/download PDF

35. Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.

Author

Khozin, Sean, primary, Zhi, Jizu, additional, Jun, Monika, additional, Chen, Li, additional, Rubinstein, Wendy S., additional, Walker, Mark S., additional, Komatsoulis, George Anthony, additional, Roberts, Jeremy, additional, Fukushima, Ryan, additional, Lau, Denise, additional, Hyde, Brigham, additional, Stepanski, Edward, additional, and Miller, Robert S., additional

Published
2019
Full Text
View/download PDF

36. Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.

Author

Rubinstein, Wendy S., primary, Chen, Li, additional, Komatsoulis, George Anthony, additional, Stepanski, Edward, additional, Jun, Monika, additional, Zhi, Jizu, additional, Lau, Denise, additional, Roberts, Jeremy, additional, Miller, Robert S., additional, Walker, Mark S., additional, Fukushima, Ryan, additional, Hyde, Brigham, additional, and Khozin, Sean, additional

Published
2019
Full Text
View/download PDF

37. Organ dysfunction (dys) and clinical outcomes in patients (pts) treated with immune checkpoint inhibitors (ICIs).

Author

LIU, QI, primary, Sharon, Elad, additional, Zineh, Issam, additional, Xie, Diqiong (Joan), additional, Baxi, Shrujal S., additional, Liu, Chao, additional, Zhi, Jizu, additional, Torres, Aracelis Z., additional, Gossai, Anala, additional, Sridhara, Rajeshwari, additional, Booth, Brian, additional, Blumenthal, Gideon Michael, additional, Huang, Shiew-Mei, additional, and Khozin, Sean, additional

Published
2019
Full Text
View/download PDF

38. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Author

Khozin, Sean, primary, Walker, Mark S., additional, Jun, Monika, additional, Chen, Li, additional, Stepanski, Edward, additional, Rubinstein, Wendy S., additional, Komatsoulis, George Anthony, additional, Roberts, Jeremy, additional, Zhi, Jizu, additional, Miller, Robert S., additional, Fukushima, Ryan, additional, Lau, Denise, additional, and Hyde, Brigham, additional

Published
2019
Full Text
View/download PDF

40. Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer

Author

Griffith, Sandra D., primary, Tucker, Melisa, additional, Bowser, Bryan, additional, Calkins, Geoffrey, additional, Chang, Che-hsu (Joe), additional, Guardino, Ellie, additional, Khozin, Sean, additional, Kraut, Josh, additional, Miksad, Rebecca, additional, You, Paul, additional, Schrag, Deb, additional, and Abernethy, Amy P., additional

Published
2019
Full Text
View/download PDF

41. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Author

Khozin, Sean, primary, Carson, Kenneth R., additional, Zhi, Jizu, additional, Tucker, Melisa, additional, Lee, Shannon E., additional, Light, David E., additional, Curtis, Melissa D., additional, Bralic, Marta, additional, Kaganman, Irene, additional, Gossai, Anala, additional, Hofmeister, Philip, additional, Torres, Aracelis Z., additional, Miksad, Rebecca A., additional, Blumenthal, Gideon Michael, additional, Pazdur, Richard, additional, and Abernethy, Amy P., additional

Published
2018
Full Text
View/download PDF

43. Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

Author

Zhi, Jizu, primary, Khozin, Sean, additional, Kuk, Deborah, additional, Torres, Aracelis Z., additional, Sorg, Rachael, additional, Lee, Shannon E., additional, Miksad, Rebecca A., additional, Pazdur, Richard, additional, and Abernethy, Amy Pickar, additional

Published
2018
Full Text
View/download PDF

48. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

Author

Khozin, Sean, primary, Abernethy, Amy P., additional, Nussbaum, Nathan C., additional, Zhi, Jizu, additional, Curtis, Melissa D., additional, Tucker, Melisa, additional, Lee, Shannon E., additional, Light, David E., additional, Gossai, Anala, additional, Sorg, Rachael A., additional, Torres, Aracelis Z., additional, Patel, Payal, additional, Blumenthal, Gideon Michael, additional, and Pazdur, Richard, additional

Published
2018
Full Text
View/download PDF

49. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus

Author

Conley, Robert B., primary, Dickson, Dane, additional, Zenklusen, Jean Claude, additional, Al Naber, Jennifer, additional, Messner, Donna A., additional, Atasoy, Ajlan, additional, Chaihorsky, Lena, additional, Collyar, Deborah, additional, Compton, Carolyn, additional, Ferguson, Martin, additional, Khozin, Sean, additional, Klein, Roger D., additional, Kotte, Sri, additional, Kurzrock, Razelle, additional, Lin, C. Jimmy, additional, Liu, Frank, additional, Marino, Ingrid, additional, McDonough, Robert, additional, McNeal, Amy, additional, Miller, Vincent, additional, Schilsky, Richard L., additional, and Wang, Lisa I., additional

Published
2017
Full Text
View/download PDF

50. Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Author

Arnerić, Stephen P., primary, Cedarbaum, Jesse M., additional, Khozin, Sean, additional, Papapetropoulos, Spyros, additional, Hill, Derek L., additional, Ropacki, Michael, additional, Rhodes, Jane, additional, Dacks, Penny A., additional, Hudson, Lynn D., additional, Gordon, Mark Forrest, additional, Kern, Volker D., additional, Romero, Klaus, additional, Vradenburg, George, additional, Au, Rhoda, additional, Karlin, Daniel R., additional, Facheris, Maurizio F., additional, Fitzer-Attas, Cheryl J., additional, Vitolo, Ottavio V., additional, Wang, Jian, additional, Miller, Bradley M., additional, and Kaye, Jeffrey A., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results